Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22432049 | 0.98 | CA2 (0.42) | CA2KAT2BNR1I2SLC6A3SLC6A4 | |
| SCHEMBL23079347 | 0.92 | CA2 (0.38) | CA2KAT2BSLC6A3SLC6A2 | |
| SCHEMBL22435683 | 0.81 | CA2 (0.39) | CA2KAT2BSLC6A3SLC6A4SLC6A2 | |
| SCHEMBL22426550 | 0.81 | CA2 (0.40) | CA2NR1I2DNM1 | |
| SCHEMBL23057959 | 0.80 | CA2 (0.41) | CA2NR1I2DNM1GPR84 | |
| SCHEMBL23057955 | 0.80 | CA2 (0.44) | CA2NR1I2GPR84 | |
| SCHEMBL22692959 | 0.78 | CA2 (0.46) | CA2NR1I2GPR84 | |
| SCHEMBL23079421 | 0.76 | CA2 (0.42) | CA2NR1I2 | |
| SCHEMBL23340313 | 0.76 | SLC6A2 (0.35) | KAT2BSLC6A3SLC6A2 | |
| SCHEMBL22435554 | 0.75 | CA2 (0.40) | CA2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210128589-A1 | PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPA1 | CA2 154/4885KAT2B 959/4885NR1I2 1922/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | CA2 154/4885KAT2B 959/4885NR1I2 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.